Home › Myeloproliferative Neoplasms › Oklahoma › Oklahoma City
Myeloproliferative Neoplasms clinical trials in Oklahoma City, OK
4 studies for Myeloproliferative Neoplasms are looking for participants at sites in and around Oklahoma City (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
RecruitingPhase 2
- University of Oklahoma Health Sciences Center, Oklahoma City
A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs)
RecruitingPhase 2
- University of Oklahoma Health Sciences Center, Oklahoma City
Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
RecruitingPhase 2
- University of Oklahoma Health Sciences Center, Oklahoma City
Project: Every Child for Younger Patients With Cancer
RecruitingObservational study
- University of Oklahoma Health Sciences Center, Oklahoma City
Myeloproliferative Neoplasms trials in other cities
- Houston, TX16 studies
- New York City, NY15 studies
- Boston, MA14 studies
- Milwaukee, WI10 studies
- Miami, FL10 studies
- Durham, NC9 studies
- Baldwin Park, CA9 studies
- Seattle, WA9 studies
- Chicago, IL9 studies
- Cleveland, OH8 studies
- Portland, OR8 studies
- Atlanta, GA8 studies
Other studies in Oklahoma City
- Non-Small Cell Lung Cancer28 studies
- Ovarian Cancer28 studies
- Endometrial Cancer25 studies
- Colorectal Cancer22 studies
- Prostate Cancer21 studies
- Lung Cancer19 studies
- Breast Cancer17 studies
- Metastatic Cancer16 studies
- Cancer (all types)14 studies
- Acute Myeloid Leukemia14 studies
- Head and Neck Squamous Cell Carcinoma13 studies
- Bladder Cancer11 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.